AC
APLS

Allstate Corporation’s Apellis Pharmaceuticals APLS Stock Holding History

Allstate Corporation’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,694
Closed -$316K – 589
2021
Q4 		$316K Buy
+6,694
New +$264K 0.01% 718
2021
Q3 		– Sell
-5,651
Closed -$357K – 694
2021
Q2 		$357K Buy
5,651
+71
+1% +$3.66K 0.01% 610
2021
Q1 		$239K Buy
5,580
+123
+2% +$5.82K 0.01% 690
2020
Q4 		$312K Buy
+5,457
New +$231K 0.01% 606
2020
Q3 		– Sell
-6,624
Closed -$216K – 668
2020
Q2 		$216K Buy
+6,624
New +$213K 0.01% 646

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allstate Corporation's APLS Position: Q1 2022 in Review

Allstate Corporation sold out of Apellis Pharmaceuticals (APLS) in Q1 2022, closing a stake of 6,694 shares — an estimated $316K sold.

Allstate Corporation first reported a position in APLS in Q2 2020 and held it in 5 quarters. The position peaked at $357K in Q2 2021. 212 funds tracked by Wall St. Rank hold APLS as of Q1 2022.

  • Allstate Corporation reported no remaining Apellis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Allstate Corporation sold 6,694 Apellis Pharmaceuticals shares in Q1 2022, an estimated $316K.
  • Allstate Corporation first reported a position in Apellis Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Allstate Corporation's Apellis Pharmaceuticals position peaked at $357K in Q2 2021.
  • 212 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2022.

Based on Allstate Corporation's 13F filing for Q1 2022, filed 16 May 2022.